{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:25:36Z","timestamp":1791915936625,"version":"4.3.4"},"reference-count":100,"publisher":"National Center for Global Health and Medicine (JST)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["GHM"],"published-print":{"date-parts":[[2021,10,31]]},"DOI":"10.35772\/ghm.2021.01083","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T22:08:35Z","timestamp":1632175715000},"page":"321-334","source":"Crossref","is-referenced-by-count":22,"title":["Treatment progress and expansion in Japan: From interferon to direct-acting antiviral"],"prefix":"10.35772","volume":"3","author":[{"given":"Yuki","family":"Tahata","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21485","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244:359-362.","DOI":"10.1126\/science.2523562"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter HJ. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990; 12:671-675.","DOI":"10.1002\/hep.1840120409"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986; 315:1575-1578.","DOI":"10.1056\/NEJM198612183152503"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991; 115:700-704.","DOI":"10.7326\/0003-4819-115-9-700"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 1993; 104:877-883.","DOI":"10.1016\/0016-5085(93)91025-D"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, Kamada T. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci. 1994; 39:977-982.","DOI":"10.1007\/BF02087547"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol. 2006; 41:17-27.","DOI":"10.1007\/s00535-005-1740-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, Shimizu Y, Inoue A, Fusamoto H, Kamada T. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 1995; 21:291-297.","DOI":"10.1002\/hep.1840210205"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996; 24:778-789.","DOI":"10.1002\/hep.510240405"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bodenheimer HC, Jr., Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997; 26:473-477.","DOI":"10.1002\/hep.510260231"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339:1485-1492.","DOI":"10.1056\/NEJM199811193392101"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339:1493-1499.","DOI":"10.1056\/NEJM199811193392102"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352:1426-1432.","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002; 35:1002-1009.","DOI":"10.1053\/jhep.2002.32672"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, Chayama K. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy \u2013 a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010; 139:1190-1197.","DOI":"10.1053\/j.gastro.2010.06.071"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., H\u00e4ussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975-982.","DOI":"10.1056\/NEJMoa020047"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958-965.","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.Nat Genet. 2009; 41:1105-1109.","DOI":"10.1038\/ng.449"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996; 334:77-81.","DOI":"10.1056\/NEJM199601113340203"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon\/ribavirin combination therapy. Hepatology. 2008; 48:38-47.","DOI":"10.1002\/hep.22339"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol. 2007; 46:403-410.","DOI":"10.1016\/j.jhep.2006.09.019"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ, Albrecht JK; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123:1061-1069.","DOI":"10.1053\/gast.2002.35950"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Oze T, Hiramatsu N, Yakushijin T, <i>et al.<\/i> Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. J Viral Hepat. 2009; 16:578-585.","DOI":"10.1111\/j.1365-2893.2009.01116.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hiramatsu N, Oze T, Yakushijin T, <i>et al.<\/i> Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat. 2009; 16:586-594.","DOI":"10.1111\/j.1365-2893.2009.01106.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Berg T, von Wagner M, Nasser S, <i>et al.<\/i> Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006; 130:1086-1097.","DOI":"10.1053\/j.gastro.2006.02.015"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology. 2007; 46:1688-1694.","DOI":"10.1002\/hep.21919"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology. 2012; 142:1340-1350 e1341.","DOI":"10.1053\/j.gastro.2012.02.015"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kr\u00e4usslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005; 11:791-796.","DOI":"10.1038\/nm1268"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012; 56:78-84.","DOI":"10.1016\/j.jhep.2011.07.016"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012; 19:e134-142.","DOI":"10.1111\/j.1365-2893.2011.01528.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol. 2014; 61:219-227.","DOI":"10.1016\/j.jhep.2014.04.004"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014; 49:941-953.","DOI":"10.1007\/s00535-014-0949-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Takehara T. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection. Expert Rev Anti Infect Ther. 2014; 12:909-917.","DOI":"10.1586\/14787210.2014.925800"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Tahata Y, Hiramatsu N, Oze T, <i>et al.<\/i> The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin. J Gastroenterol. 2016; 51:252-259.","DOI":"10.1007\/s00535-015-1105-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Hayashi N, Nakamuta M, Takehara T, Kumada H, Takase A, Howe AY, Ludmerer SW, Mobashery N. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. J Gastroenterol. 2016; 51:390-403.","DOI":"10.1007\/s00535-015-1120-x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kumada H, Mochida S, Suzuki F, Chayama K, Karino Y, Nakamura K, Fujimoto G, Howe AY, Ludmerer SW, Mobashery N. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies. J Gastroenterol Hepatol. 2016; 31:1674-1683.","DOI":"10.1111\/jgh.13328"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kumada H, Suzuki Y, Ikeda K, <i>et al.<\/i> Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59:2083-2091.","DOI":"10.1002\/hep.27113"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Jacobson IM, Gordon SC, Kowdley KV, <i>et al.<\/i> Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368:1867-1877.","DOI":"10.1056\/NEJMoa1214854"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Lawitz E, Mangia A, Wyles D, <i>et al.<\/i> Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med.2013; 368:1878-1887.","DOI":"10.1056\/NEJMoa1214853"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Zeuzem S, Dusheiko GM, Salupere R, <i>et al.<\/i> Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014; 370:1993-2001.","DOI":"10.1056\/NEJMoa1316145"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Afdhal N, Reddy KR, Nelson DR, <i>et al.<\/i> Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370:1483-1493.","DOI":"10.1056\/NEJMoa1316366"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Afdhal N, Zeuzem S, Kwo P, <i>et al.<\/i> Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370:1889-1898.","DOI":"10.1056\/NEJMoa1402454"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Omata M, Nishiguchi S, Ueno Y, <i>et al.<\/i> Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014; 21:762-768.","DOI":"10.1111\/jvh.12312"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Mizokami M, Yokosuka O, Takehara T, <i>et al.<\/i> Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015; 15:645-653.","DOI":"10.1016\/S1473-3099(15)70099-X"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Morio K, Imamura M, Kawakami Y, <i>et al.<\/i> ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. J Gastroenterol. 2017; 52:746-753.","DOI":"10.1007\/s00535-016-1279-9"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Urabe A, Sakamori R, Tahata Y, <i>et al.<\/i> Predictive factors of anemia during sofosbuvir and ribavirin therapy for genotype 2 chronic hepatitis C patients. Hepatol Res. 2019; 49:853-859.","DOI":"10.1111\/hepr.13354"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Akahane T, Kurosaki M, Itakura J, <i>et al.<\/i> Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatol Res. 2019; 49:264-270.","DOI":"10.1111\/hepr.13246"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Ogawa E, Furusyo N, Nomura H, <i>et al.<\/i> NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017; 52:845-854.","DOI":"10.1007\/s00535-016-1290-1"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Tsuji K, Kurosaki M, Itakura J, <i>et al.<\/i> Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol. 2018; 53:1142-1150.","DOI":"10.1007\/s00535-018-1455-1"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Tahata Y, Sakamori R, Urabe A, <i>et al.<\/i> Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir\/Sofosbuvir Treatment for Patients With Chronic Hepatitis C. Hepatol Commun. 2018; 2:884-892.","DOI":"10.1002\/hep4.1206"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017; 89:284-290.","DOI":"10.1002\/jmv.24617"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Asahina Y, Itoh Y, Ueno Y, <i>et al.<\/i> Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver Int. 2018; 38:1552-1561.","DOI":"10.1111\/liv.13685"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 2020; 50:791-816.","DOI":"10.1111\/hepr.13503"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Doi A, Sakamori R, Tahata Y, <i>et al.<\/i> Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort. Hepatol Res. 2017; 47:1438-1444.","DOI":"10.1111\/hepr.12919"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus\/hepatitis C virus co-infection. Hepatol Res. 2016; 46:489-491.","DOI":"10.1111\/hepr.12578"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Kumada H, Chayama K, Rodrigues L, <i>et al.<\/i> Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015; 62:1037-1046.","DOI":"10.1002\/hep.27972"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Atsukawa M, Tsubota A, Koushima Y, <i>et al.<\/i> Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res. 2017; 47:1429-1437.","DOI":"10.1111\/hepr.12910"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Kumada H, Suzuki Y, Karino Y, <i>et al.<\/i> The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II\/III study. J Gastroenterol. 2017; 52:520-533.","DOI":"10.1007\/s00535-016-1285-y"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Suda G, Kurosaki M, Itakura J, <i>et al.<\/i> Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. J Gastroenterol. 2019; 54:78-86.","DOI":"10.1007\/s00535-018-1495-6"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Toyota J, Karino Y, Suzuki F, <i>et al.<\/i> Daclatasvir\/asunaprevir\/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol. 2017; 52:385-395.","DOI":"10.1007\/s00535-016-1245-6"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Takehara T, Chayama K, Kurosaki M, <i>et al.<\/i> JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. J Gastroenterol. 2020; 55:640-652.","DOI":"10.1007\/s00535-020-01672-0"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Chayama K, Suzuki F, Karino Y, <i>et al.<\/i> Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2018; 53:557-565.","DOI":"10.1007\/s00535-017-1391-5"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Toyoda H, Chayama K, Suzuki F, <i>et al.<\/i> Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018; 67:505-513.","DOI":"10.1002\/hep.29510"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Kumada H, Watanabe T, Suzuki F, <i>et al.<\/i> Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018; 53:566-575.","DOI":"10.1007\/s00535-017-1396-0"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Izumi N, Takehara T, Chayama K, <i>et al.<\/i> Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int. 2018; 12:356-367.","DOI":"10.1007\/s12072-018-9878-6"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Takehara T, Sakamoto N, Nishiguchi S, <i>et al.<\/i> Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87-95.","DOI":"10.1007\/s00535-018-1503-x"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Reig M, Mari\u00f1o Z, Perell\u00f3 C, I\u00f1arrairaegui M, Ribeiro A, Lens S, D\u00edaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016; 65:719-726.","DOI":"10.1016\/j.jhep.2016.04.008"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016; 65:727-733.","DOI":"10.1016\/j.jhep.2016.06.015"},{"key":"69","unstructured":"69. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017; S0168-8278(17)32273-0."},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Nahon P, Layese R, Bourcier V, <i>et al.<\/i> Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology. 2018; 155:1436-1450 e1436.","DOI":"10.1053\/j.gastro.2018.07.015"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Carrat F, Fontaine H, Dorival C, <i>et al.<\/i> Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019; 393:1453-1464.","DOI":"10.1016\/S0140-6736(18)32111-1"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Tahata Y, Sakamori R, Urabe A, <i>et al.<\/i> Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment. Hepatol Res, 2019.","DOI":"10.1111\/hepr.13454"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Kanwal F, Kramer JR, Asch SM, Cao Y, Li L, El-Serag HB. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020; 71:44-55.","DOI":"10.1002\/hep.30823"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Degasperi E, D&apos;Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. Clin Gastroenterol Hepatol. 2019; 17:1183-1191 e1187.","DOI":"10.1016\/j.cgh.2018.10.038"},{"key":"75","unstructured":"75. Calvaruso V, Cabibbo G, Cacciola I, <i>et al.<\/i> Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2018; 155:411-421 e414."},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Ogawa E, Furusyo N, Nomura H, <i>et al.<\/i> Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 2018; 47:104-113.","DOI":"10.1111\/apt.14380"},{"key":"77","unstructured":"77. Nahon P, Bourcier V, Layese R, <i>et al.<\/i> Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology. 2017; 152:142-156 e142."},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.Clin Gastroenterol Hepatol. 2011; 9:509-516 e501.","DOI":"10.1016\/j.cgh.2011.03.004"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology. 2019; 69:487-497.","DOI":"10.1002\/hep.29408"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Tahata Y, Sakamori R, Urabe A, Yamada R, Ohkawa K, Hiramatsu N, Hagiwara H, Oshita M, Imai Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatol Res. 2020; 50:1118-1127.","DOI":"10.1111\/hepr.13547"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, Friedrich-Rust M, Sarrazin C, Zeuzem S, Welker MW. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat. 2016; 23:994-1002.","DOI":"10.1111\/jvh.12578"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Bachofner JA, Valli PV, Kr\u00f6ger A, <i>et al.<\/i> Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017; 37:369-376.","DOI":"10.1111\/liv.13256"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Lens S, Alvarado-Tapias E, Marino Z, <i>et al.<\/i> Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology. 2017; 153:1273-1283 e1271.","DOI":"10.1053\/j.gastro.2017.07.016"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Lens S, Baiges A, Alvarado-Tapias E, <i>et al.<\/i> Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020; 73:1415-1424.","DOI":"10.1016\/j.jhep.2020.05.050"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Mandorfer M, Kozbial K, Schwabl P, <i>et al.<\/i> Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016; 65:692-699.","DOI":"10.1016\/j.jhep.2016.05.027"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Itakura J, Kurosaki M, Hasebe C, <i>et al.<\/i> Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir\/Asunaprevir Treatment Failure. PLoS One. 2016; 11:e0165339.","DOI":"10.1371\/journal.pone.0165339"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Itakura J, Kurosaki M, Kakizaki S, <i>et al.<\/i> Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C. JHEP Rep. 2020; 2:100138.","DOI":"10.1016\/j.jhepr.2020.100138"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Doi A, Hikita H, Sakamori R, Tahata Y, Kai Y, Yamada R, Yakushijin T, Mita E, Ohkawa K, Imai Y, Furuta K, Kodama T, Tatsumi T, Takehara T. Nonstructural protein 5A\/P32 deletion after failure of ledipasvir\/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology. 2018; 68:380-383.","DOI":"10.1002\/hep.29836"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Hikita H, Takehara T. NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors. Semin Liver Dis. 2020; 40:143-153.","DOI":"10.1055\/s-0039-3402001"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Osawa M, Imamura M, Teraoka Y, <i>et al.<\/i> Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol. 2019; 54:291-296.","DOI":"10.1007\/s00535-018-1520-9"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1\/2\/3 infections. J Gastroenterol. 2019; 54:916-927.","DOI":"10.1007\/s00535-019-01575-9"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Uemura H, Uchida Y, Kouyama JI, Naiki K, Tsuji S, Sugawara K, Nakao M, Motoya D, Nakayama N, Imai Y, Tomiya T, Mochida S. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol. 2019; 54:459-470.","DOI":"10.1007\/s00535-018-01543-9"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Takaki S, Imamura M, Yamaguchi S, Fukuhara T, Mori N, Tsuji K, Ohya K, Hayes CN, Aikata H, Chayama K. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clin J Gastroenterol. 2020; 13:1233-1238.","DOI":"10.1007\/s12328-020-01182-9"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Nonomura A, Tamori A, Hai H, Kozuka R, Fujii H, Uchida-Kobayashi S, Enomoto M, Kawada N. Sofosbuvir\/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir\/Pibrentasvir Therapy Failed. Intern Med. 2021.","DOI":"10.2169\/internalmedicine.7028-21"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Maesaka K, Sakamori R, Yamada R, <i>et al.<\/i> Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. Hepatol Res. 2021; 51:517-527.","DOI":"10.1111\/hepr.13623"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Tahata Y, Hikita H, Mochida S, <i>et al.<\/i> Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021; 56:67-77.","DOI":"10.1007\/s00535-020-01733-4"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Takaoka Y, Miura K, Morimoto N, <i>et al.<\/i> Real-world efficacy and safety of 12-week sofosbuvir\/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res. 2021; 51:51-61.","DOI":"10.1111\/hepr.13576"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Atsukawa M, Tsubota A, Kondo C, <i>et al.<\/i> Real-World Clinical Application of 12-Week Sofosbuvir\/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infect Dis Ther. 2020; 9:851-866.","DOI":"10.1007\/s40121-020-00329-y"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Verna EC, Morelli G, Terrault NA, <i>et al.<\/i> DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020; 73:540-548.","DOI":"10.1016\/j.jhep.2020.03.031"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, de Knegt RJ, Hansen BE, Janssen HLA, de Man RA, Feld JJ, van der Meer AJ. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021; 74:1053-1063.","DOI":"10.1016\/j.jhep.2020.11.021"}],"container-title":["Global Health &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/3\/5\/3_2021.01083\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T03:43:18Z","timestamp":1636774998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ghm\/3\/5\/3_2021.01083\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.35772\/ghm.2021.01083","relation":{},"ISSN":["2434-9186","2434-9194"],"issn-type":[{"value":"2434-9186","type":"print"},{"value":"2434-9194","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"article-number":"2021.01083"}}